0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CTLA-4

CTLA-4

Brief Information

Name:Cytotoxic T-Lymphocyte-Associated Antigen 4
Target Synonym:CD152,Cytotoxic T-lymphocyte-associated antigen 4,CTLA4,CTLA-4,Cytotoxic T-Lymphocyte Associated Protein 4,Insulin-Dependent Diabetes Mellitus 12,Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form,Cytotoxic T-Lymphocyte-Associated Serine Ester
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:32
Lastest Research Phase:Approved

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CT4-H82A3 Human Biotinylated Human CTLA-4 Protein, Mouse IgG2a Fc,Avitag™
CT4-H82A3-structure
CT4-H82A3-sds
CT4-H82A3-elisa_1
CT4-H52H9 Human Human CTLA-4 / CD152 Protein, His Tag, active dimer (MALS verified)
CT4-H52H9-sds
CT4-H52H9-elisa_1
CT4-H82E3 Human Biotinylated Human CTLA-4 Protein, His,Avitag™ (MALS verified)
CT4-H82E3-structure
CT4-H82E3-sds
CT4-H82E3-elisa_1
CT4-H82E3-elisa_2
CT4-M82E7 Mouse Biotinylated Mouse CTLA-4 Protein, His,Avitag™
CT4-M82E7-structure
CT4-M82E7-sds
CT4-M82E7-elisa_1
ECH-V1 Human ELISA Assay Kit for Anti-CTLA-4 h-mAb in Human Serum
ECH-V1-elisa_1
ECC-V1 Monkey ELISA Assay Kit for Anti-CTLA-4 h-mAb in Monkey Serum
ECC-V1-elisa_1
ECM-V1 Mouse ELISA Assay Kit for Anti-CTLA-4 h-mAb in Mouse Serum
ECM-V1-elisa_1
CT4-H522a Human Human CTLA-4 / CD152 Protein, His Tag, low endotoxin
CT4-H522a-structure
CT4-H522a-sds
CT4-H522a-elisa_1
CT4-H82E1 Human Biotinylated Human CTLA-4 Protein, His,Avitag™
CT4-H82E1-structure
CT4-H82E1-sds
CT4-H82E1-elisa_1
CT4-H52A4 Human Human CTLA-4 / CD152 Protein, mouse IgG2a Fc Tag, low endotoxin
CT4-H52A4-structure
CT4-H52A4-sds
CT4-H52A4-elisa_1
CT4-R5250 Rabbit Rabbit CTLA-4 / CD152 Protein, Fc Tag
CT4-R5250-structure
CT4-R5250-sds
CT4-R5250-elisa_1
CT4-R5259 Rat Rat CTLA-4 / CD152 Protein, Fc Tag
CT4-R5259-structure
CT4-R5259-sds
CT4-R5259-elisa_1
CT4-M5256 Mouse Mouse CTLA-4 / CD152 Protein, Fc Tag
CT4-M5256-structure
CT4-M5256-sds
CT4-M5256-elisa_1
CT4-M52H5 Mouse Mouse CTLA-4 / CD152 Protein, His Tag
CT4-M52H5-structure
CT4-M52H5-sds
CT4-M52H5-elisa_1
CT4-H82F3 Human Biotinylated Human CTLA-4 Protein, Fc,Avitag™
CT4-H82F3-structure
CT4-H82F3-sds
CT4-H82F3-elisa_1
CT4-C82E5 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque CTLA-4 Protein, Avitag™,His Tag
CT4-C82E5-structure
CT4-C82E5-sds
CT4-C82E5-elisa_1
CT4-C5227 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CTLA-4 Protein, His Tag
CT4-C5227-structure
CT4-C5227-sds
CT4-C5227-elisa_1
CT4-C5256 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CTLA-4 Protein, Fc Tag
CT4-C5256-structure
CT4-C5256-sds
CT4-C5256-elisa_1
CT4-H5255 Human Human CTLA-4 / CD152 Protein, Fc Tag
CT4-H5255-structure
CT4-H5255-sds
CT4-H5255-elisa_1
CT4-H5229 Human Human CTLA-4 / CD152 Protein, His Tag
CT4-H5229-structure
CT4-H5229-sds
CT4-H5229-elisa_1
CT4-H5229-elisa_2

Part of Bioactivity data

CT4-H82E3-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human CTLA-4, His,Avitag (Cat. No. CT4-H82E3) captured on Biotin CAP - Series S sensor Chip can bind Yervoy (Ipilimumab) with an affinity constant of 0.635 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CT4-H5229-SPR
Human_FcRn_Heterodimer_Protein_SPR

Yervoy (Ipilimumab, Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CTLA-4, His Tag (Cat. No. CT4-H5229) with an affinity constant of 25.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name

CTLA4,CD152

Background

CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ipilimumab 10D1; MDX-010; MDX-101; Mab-10D14; BMS-734016; MDX-CTLA-4; Anti-CTLA-4 Mab Approved Bristol-Myers Squibb Company Yervoy EU Colorectal Neoplasms Bristol-Myers Squibb Pharma Eeig 2011-03-25 Microsatellite instability-high cancer; Adenocarcinoma; Large intestine neoplasm; Carcinoma, Hepatocellular; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Lung Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Multiple Myeloma; Liver Neoplasms; Mesothelioma; Uveal melanoma; Hodgkin Disease; Dermatofibrosarcoma; Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; HIV Infections; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CTLA-4 monoclonal antibody (Regeneron) REGN-4659 Phase 1 Clinical Regeneron Pharmaceuticals Inc Carcinoma, Non-Small-Cell Lung Details
B7-2/GM-CSF cancer gene therapy CIT Phase 1 Clinical Radient Neoplasms Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) Phase 2 Clinical Shanghai Cell Therapy Research Institute Neoplasms Details
BCD-217 BCD-217 Phase 2 Clinical Biocad Melanoma Details
Recombinant anti-CTLA-4 human monoclonal antibody (Henlius) Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma Details
IO-102 IO-102 Phase 2 Clinical Herlev Hospital, Merck Sharp & Dohme Corp, Io Biotech Carcinoma, Non-Small-Cell Lung; Melanoma Details
FPT-155 CD80-Fc; FPT-155 Phase 1 Clinical Five Prime Therapeutics Neoplasms Details
ATOR-1015 ADC-1015; ATOR-1015 Phase 1 Clinical Alligator Bioscience Neoplasms Details
Abatacept (Orban Biotech) Phase 2 Clinical Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases Diabetes Mellitus, Type 1 Details
RP-2 RP-2 Phase 1 Clinical Replimune, Bristol-Myers Squibb Company Neoplasms Details
BMS-986249 BMS-986249 Phase 2 Clinical Cytomx Therapeutics Neoplasms Details
Anti-CTLA-4 antibody (Agenus) AGEN-1181 Phase 2 Clinical Agenus Inc Neoplasms Details
IDO-derived peptide vaccine/PD-L1-derived peptide vaccine IO-102/IO-103 Phase 2 Clinical Herlev Hospital Melanoma Details
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) Phase 2 Clinical Hualan Genetic Engineering Co Ltd Melanoma Details
BT-001 BT-001 Phase 2 Clinical Transgene Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
ADG-116 ADG-116; ADG116 Phase 1 Clinical Adagene (Suzhou) Ltd Neoplasms Details
MEDI-5752 MEDI-5752 Phase 1 Clinical Medimmune Llc Solid tumours; Carcinoma, Renal Cell; Neoplasms Details
KN-044 KN-044 Phase 1 Clinical Suzhou Alphamab Co Ltd Solid tumours Details
ONCR-177 ONCR-177 Phase 1 Clinical Oncorus Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
CS-1002 CS-1002 Phase 1 Clinical Cstone Pharmaceuticals Solid tumours Details
MGD-019 (MacroGenics) MGD-019 Phase 1 Clinical Macrogenics Solid tumours; Skin Melanoma; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HBM-4003 HBM-4003 Phase 1 Clinical Harbour Biomed Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung Details
ADG-126 Phase 1 Clinical Adagene Inc Neoplasms; Neoplasm Metastasis Details
YH-001 YH-001 Phase 2 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours; Melanoma Details
JS-007 JS-007 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Neoplasms; Lung Neoplasms; Melanoma Details
XmAb-22841 XmAb-22841 Phase 1 Clinical Xencor Cholangiocarcinoma; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Penile Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Microsatellite Instability; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck Details
ALPN-202 ALPN-202 Phase 1 Clinical Alpine Immune Sciences Solid tumours; Lymphoma Details
SI-B003 SI-B003 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
BA3017 BA-3017; BA3017 Phase 1 Clinical Bioatla Neoplasms Details
Zalifrelimab AGEN-1884; RebmAb-600 Phase 2 Clinical 4-Antibody, Ludwig Institute For Cancer Research Solid tumours; Hemangiosarcoma; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
BAT-4706 BAT-4706 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Melanoma Details
ONC-392 ONC-392 Phase 1 Clinical Oncoimmune Small Cell Lung Carcinoma; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Solid tumours; Pancreatic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms Details
XTX-101 XTX-101 Phase 2 Clinical Solid tumours Details
GI-101 GI-101 Phase 2 Clinical Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Recombinant human anti-CTLA-4 monoclonal antibody (Mab-Venture/ShuangLu Pharmaceutical) Phase 1 Clinical Shanghai Mab-Venture Biopharm Co Ltd, Beijing Sl Pharmaceutical Co Ltd Solid tumours Details
Tremelimumab CP-675; CP-675206 Phase 3 Clinical Pfizer Inc Lymphoma, Large B-Cell, Diffuse; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Urogenital Neoplasms; Fallopian Tube Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Digestive System Neoplasms; Hematologic Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Esophageal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Head and Neck Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Solid tumours Details
Quavonlimab MK-1308; AK-107 Phase 2 Clinical Merck Sharp & Dohme Corp Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
QL-1706 QL-1706; PSB-205 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Solid tumours; Liver Neoplasms; Neoplasms Details
Ipilimumab biosimilar (Innovent Biologics) IBI-310 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd Liver Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
XmAb20717 XmAb-20717 Phase 2 Clinical Xencor Breast Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Thymoma; Colorectal Neoplasms; Astrocytoma; Prostatic Neoplasms; Vulvar Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Adnexal Diseases; Mesothelioma; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell Details
AK-104 AK-104 Phase 3 Clinical Zhongshan Akeso Biopharma Co Ltd Lymphoma, T-Cell, Peripheral; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Microsatellite instability-high cancer; Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
KN-046 KN046; KN-046 Phase 3 Clinical Suzhou Alphamab Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details

This web search service is supported by Google Inc.

totop